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Well-designed epidemiologic studies are the
desired approach for defining the relationships
between environmental exposures and human
disease. This is partly because human health
studies provide the research framework for
addressing issues of individual susceptibility to
exposure and disease. Furthermore, they are
much richer in relevant information than is
simple extrapolation from laboratory studies
with nonhuman models. This is underscored
in recent articles highlighting the importance
of designing studies in which interactions
between the environment and genetics can be
examined to address important health out-
comes (Collins 2004; Potter 2004). There is
wide agreement in the scientific community
that diseases that contribute the greatest pub-
lic health burden to society result from com-
plex interactions between genetic and
environmental factors, such as chemical pollu-
tants, nutrition, lifestyle, infectious agents,
and stress (Doll and Peto 1981; Hemminki
et al. 2001; World Cancer Research Fund
Panel 1997). Environmental factors are an
attractive target for disease prevention, espe-
cially when susceptible subgroups within the
population can be identified. The lack of
accurate, quantitative measures of exposure,
and information about their relationship to
one another and to disease, is the greatest
source of uncertainty in epidemiologic studies,
limiting the power of such studies to enable
definitive conclusions about the association
between exposure and disease. New technolo-
gies are available for improving exposure
assessment in human health investigations and
can be exploited in environmental health
research, creating a public health strategy for
guiding health research and for translating
basic research findings into effective preven-
tion, intervention, and treatment efforts.
Exposure Assessment
Methods
The cornerstone of exposure assessment in
epidemiologic studies is the development of
the exposure metric, the estimate of exposure
for each individual of the study population.
Ideally, the metric is developed independently
for each individual using an actual measure-
ment of exposure that can be validated
(Schulte and Perera 1993). Typically, the
exposure metric is based on the concentration
of specific chemicals, their metabolites, or
reaction products in a biologic sample such as
blood, urine, or saliva. Obtaining an actual
exposure measurement may not be practical
when the exposure has occurred in the past
and can no longer be detected in a biologic
sample. In these instances, the metric is usu-
ally developed from environmental monitor-
ing data and chemical transport and fate
models using assumptions about the activity
patterns and age-specific variables that predict
exposure in relation to frequency, duration,
and route of entry into the body [Lioy 1990;
U.S. Environmental Protection Agency (EPA)
1989). Thus, a theoretical construct is devel-
oped for estimating potential exposure to
hypothetical or actual individuals of the study
population. Uncertainty is an obvious concern
when the exposure assessment is derived from
a theoretical rather than an evidence-based
construct.
Epidemiology relies on inference of associ-
ations between exposure and response vari-
ables. Typically, the measurements of response
in epidemiologic studies reflect late-stage end
points of morbidity, mortality, body weight
decrease, tumor development, and tissue
pathology (Bocchetta and Carbone 2004;
Maier et al 2004). Defining risk at a late stage
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New technologies and methods for assessing human exposure to chemicals, dietary and lifestyle
factors, infectious agents, and other stressors provide an opportunity to extend the range of
human health investigations and advance our understanding of the relationship between environ-
mental exposure and disease. An ad hoc Committee on Environmental Exposure Technology
Development was convened to identify new technologies and methods for deriving personalized
exposure measurements for application to environmental health studies. The committee identified
a “toolbox” of methods for measuring external (environmental) and internal (biologic) exposure
and assessing human behaviors that influence the likelihood of exposure to environmental agents.
The methods use environmental sensors, geographic information systems, biologic sensors, toxico-
genomics, and body burden (biologic) measurements. We discuss each of the methods in relation
to current use in human health research; specific gaps in the development, validation, and applica-
tion of the methods are highlighted. We also present a conceptual framework for moving these
technologies into use and acceptance by the scientific community. The framework focuses on
understanding complex human diseases using an integrated approach to exposure assessment to
define particular exposure–disease relationships and the interaction of genetic and environmental
factors in disease occurrence. Improved methods for exposure assessment will result in better
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in the disease process provides little opportu-
nity to intervene and redirect the outcome. It
is clearly more desirable to identify early
changes in biologic processes that can serve as
predictive markers of exposure, of early effect,
or of susceptibility [Committee on Biological
Markers of the National Research Council
(NRC) 1987]. These components of the pro-
posed continuum between exposure and dis-
ease have been described in a number of
reports (Lioy 1990; Maier et al. 2004; NRC
1987; Omenn 2002; Perera and Weinstein
1982; Pesch et al. 2004; Schulte 1989; Waters
and Fostel 2004). It is important to remember
that the distinctions between exposure and
response in this continuum are arbitrary. As
scientists, we are not able to measure dynamic
biologic processes in real time; instead, we
must rely on static measurements made at a
single or multiple time points. Thus, some
markers may represent the event of interest, or
may be the event itself, or may be a predictor
of the event (Goldstein 1995; Schulte and
Perera 1993). This point is illustrated in
Figure 1 using data from several human stud-
ies evaluating genetic and biologic markers of
susceptibility, biologically effective dose, and
carcinogenesis from exposure to polycyclic
aromatic hydrocarbons (PAHs) in tobacco
smoke and urban air (Mooney et al. 2005;
Perera et al. 2002, 2004; Poirier and Beland
1992; Rundle et al. 2000; Tang et al. 1995;
Veglia et al. 2003). Collectively, the findings
illustrate that genetic and biologic markers
reflect different biologic events in the overall
exposure–disease continuum. The events do
not necessarily reflect linearity, although they
may be related, nor do they conform to the
conventional boundaries for exposure and
response. Appropriately, the assessment of
exposure and risk should focus on understand-
ing the biologic processes of human disease by
defining markers that represent and can link
events, both genetic and environmental, in the
exposure–disease relationship. In this context,
there are multiple approaches for defining the
relationship between exposure and disease;
some of these will be based on qualitative data
that are not readily amenable to conventional
dose–response analysis, and each will require a
specialized assessment and validation strategy
(Rebbeck et al. 2004a; Schulte and Perera
1993).
The biologic response to environmental
exposure occurs as a result of complex inter-
actions between multiple genetic, environmen-
tal, and behavioral factors, highlighting the
importance of defining markers of genetic vari-
ation that confer differential functional signifi-
cance in target cellular pathways. Several
programs supported by the National Institute
of Environmental Health Sciences (NIEHS),
such as the Environmental Genome Project
and Children’s Environmental Health Sciences
Centers, focus on identifying genetic determi-
nants of susceptibility and the role of gene–
environment interactions in disease (Gilliland
et al. 2002a, 2002b; Lan et al. 2004; Rollinson
et al. 2004; Skibola et al. 2004). For example,
a cross-sectional study of benzene-exposed
shoe workers (Lan et al. 2004) identified two
genetic variants in key metabolizing enzymes,
myeloperoxidase and NAD(P)H:quinone
oxidoreductase, that influence susceptibility to
benzene hematotoxicity, showing a strong
gene–dose effect that persisted in workers
exposed to benzene at very low levels
(< 1 ppm). The findings are particularly robust
in relation to previous occupational studies of
benzene-induced hematotoxicity because, in
this study, personalized exposure monitoring
was conducted over a 16-month period and
individual air monitoring was linked to specific
end points of toxicity. The study highlights the
use of personalized exposure and genetic infor-
mation to define individual susceptibility.
Despite recent advances in genetic suscep-
tibility studies, challenges remain in defining
the functional significance of genetic variants
and their interaction with environmental fac-
tors in biologic systems. In general, health
researchers lack reliable, high-throughput,
and cost-effective approaches to measure early
changes in biologic processes, particularly at
the molecular level. The information can pro-
vide insight into the biologic and health sig-
nificance of genetic variants in human
populations. Even when information about
early molecular and cellular events is available,
it is often difficult to interpret in relation to a
point of departure from normal physiologic
adaptive response to adverse response. At pre-
sent, the usual information available generally
provides limited insight into the relationship
between exposure and health risk in individuals
or populations.
An ad hoc Committee on Environmental
Exposure Technology Development met sev-
eral times during the summer of 2004 to iden-
tify new technologies and methods for
improving exposure assessment in human
health research. The committee identified a
“toolbox” of methods that can be used alone or
in combinations to provide information about
individual exposure for a variety of exposure
scenarios (Lioy 1995). Certain methods within
the toolbox, such as environmental sensors and
geographic information systems (GIS), can be
used to derive information about external
environmental exposures and the personal
activity patterns that influence the magnitude,
frequency, duration, and pathways of exposure.
Other methods, such as biologic sensors, toxi-
cogenomics, and body burden assays, can be
used to derive measurements of internal bio-
logic exposure. Linking the data sets across
multiple scales provides an integrated view of
exposure that is needed to define complex
exposure–disease relationships and the inter-
play between genes, environmental factors, and
behavior in disease occurrence (Lioy 1995;
Maier et al. 2004). We discuss each of these
methods in relation to current applicability to
human health studies; we also identify specific
gaps in the development, validation, and appli-
cation of the methods. We identified specific
activities as first-generation (first 5 years) and
second-generation (5–10 years) priorities for
moving these technologies into full use and
acceptance by the scientific community
(Table 1). Finally, the committee developed a
conceptual framework for integrating these
new technologies in human health studies
(Figure 2). The strategy identifies elements of
Personalized exposure assessment
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Figure 1. A schematic representation of markers of exposure, response, and susceptibility in the
exposure–disease continuum: an example for PAHs and cancer. CYP2A6, cytochrome P4502A6 gene; ETS,
environmental tobacco smoke; GSTM1, glutathione S-transferase M1 gene; PAHs, polycyclic aromatic
hydrocarbons; Arrows indicate predictability of each marker for exposure or disease in the exposure–
disease continuum. Adapted from NRC (1987). PAHs in ETS and urban air are a marker for exposure source.
GSTM1 null genotype and blood PAH–DNA adducts are independent markers of cancer case status (dis-
ease) but have a multiplicative effect in combination (Perera et al. 2002; Tang et al. 1995). GSTM1 null geno-
type is a predictor of tissue PAH–DNA adducts, which are a marker for altered function (Perera et al. 2002;
Rundle et al. 2000; Tang et al. 1995). CYP2A6 variant is a marker for increased internal dose of nicotine and
protective effect on cancer development (Spitz et al. 2005). Plasma cotinine is a marker for internal expo-
sure to ETS but is not correlated with blood PAH–DNA adducts (Mooney et al. 2005). Blood PAH adducts
are a marker for PAH/ETS exposure, internal dose, biologically effective dose, early biologic response, and
cancer (Mooney et al. 2005; Perera et al. 2002, 2004; Poirier and Beland 1992; Veglia et al. 2003; Whyatt et al.
1998). Tissue PAH–DNA adducts are a marker for altered function and cancer (Rundle et al. 2000). 
Exposure
source
Transport
and fate
External
contact
Internal
dose
Biologically
effective
dose
Early
biologic
response
Altered
function
Clinical
disease
CYPA26
variant
genotype
Markers PAHs in ETS
and urban air
GSTM1 null
genotype
Plasma
cotinine
Blood PAH–DNA adducts Tissue PAH–DNA adducts
the study design and implementation where
new approaches to human-exposure assess-
ment can be incorporated. Implementation of
the strategy focuses on common complex
human diseases, such as asthma and respira-
tory disease, neurodegenerative disease, and
cancer, each of which represents a significant
public health burden to society. Adopting a
disease-first approach to exposure assessment
allows researchers to take full advantage of
new scientific approaches that are currently
available in order to advance current knowl-
edge about important diseases (Wilson and
Suk, in press). In addition, for each of these
outcomes there is substantial evidence of
genetic and environmental risk, providing a
logical basis for focusing new health research,
prevention, and intervention efforts.
Environmental Exposure
Methods
Environmental sensors. Environment-sensing
devices provide exposure information on a
variety of scales, including macro-level expo-
sures in the ambient environment such as from
industrial effluents; microscale exposures in the
household, workplace, and personal environ-
ment; and nanoscale exposures at the points of
human contact. Over the past 15 years, there
has been significant progress in the develop-
ment of sensors for monitoring a variety of
chemical and biologic agents in the ambient
and personal environment (Cui et al. 2001;
Georgieva et al. 2002; Haruyama 2003; Svitel
et al. 2001). Macroscale technologies such as
laser-based and infrared-radiation–based sen-
sors are currently being used for assessing
population exposures to sulfur and nitric
oxides in industrial-stack effluents. Other
microscale sensors, including personal dosime-
ters, are being used to monitor levels of carbon
dioxide, carbon monoxide, volatile organic
compounds, pesticides, and PAHs in the
workplace, household, and personal environ-
ment. The benefits of using microscale over
macroscale devices for environmental agents
include increased sensitivity for a range of
compound classes, decreased volumes of ana-
lytic reagents, and increased throughput and
potential for multiplexing.
New technologies to assess environmental
exposures at the personal level are being con-
ceived, but development is moving slowly.
Recent efforts have focused on automated
“lab-on-a-chip” sensing devices for detecting
environmental agents (Hood et al. 2004). The
devices deliver nanoscale volumes of sample to
a detection element based on electricity, fluo-
rescence, affinity, or cell function. The sensors
can be very small, inexpensive, and easy to use
and offer the potential for continuous moni-
toring on a global or microscale, making them
ideal tools for monitoring personal exposure to
individual compounds and mixtures.
The use of environmental sensors for large
human studies will remain elusive until impor-
tant issues related to sample handling and con-
trol, comprehensiveness of analytic probes, and
validation of results are adequately addressed.
Targeted efforts by academic researchers and
industry are needed, in the short term, to
develop sensing devices to accurately and reli-
ably measure high-priority environmental
agents, including chemical and biologic agents
and complex mixtures, in small-scale projects
that have the potential for scalability. This
remains an unmet need that was identified in
the NRC report on exposure assessment (NRC
1991). Some efforts could build on existing
technological developments of counter-
measures against bioweapons based on bacte-
ria, viruses, and toxins (Brown 2004). Personal
monitors could include global-positioning
systems so that the changes in exposure could
be tracked as an individual moves through the
environment. In aggregate, this could enable
researchers to develop data sets that allow
mapping and modeling of patterns of expo-
sures across communities.
GIS technology. GIS technology is now an
increasingly popular tool for developing the
exposure metric in epidemiologic studies
(Beyea and Hatch 1999; Jarup 2004; Nuckols
et al. 2004). The technology is used to create
distinct electronic data displays or layers that
can be linked spatially and temporally using
mathematical modeling systems or tools. The
data displays are created by piecing together
available environmental, population, and
land-use data sets. Many of the available
Weis et al.
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Table 1. A toolbox of promising exposure assessment technologies and activities for integration in human
environmental health research.
Technology First-generation activities Second-generation activities
All technologies Identify priority diseases, plausible Develop background ranges and study
environmental exposure factors (including population distribution of parameters
dietary and lifestyle factors, infectious for priority environmental exposures,
agents), genetic determinants, biologic response parameters, and genetic
pathways, and model systems variants
Identify and review available scientific
literature and databases in government,
academia, and industry
Convene a workshop of experts to establish
research priorities.
Environmental sensors Develop and validate in vitro sensors for Develop multiplexed sensors for 
detecting and quantifying priority continuous monitoring of priority
environmental exposures environmental exposures
Develop analytic tools and approaches Develop integrated sensor networks
to link environmental data across
multiple scales, from macroenvironmental
to personal
GIS technology Select priority environmental and population Initiate studies using environmental
data sets and develop GIS displays and biologic sensors and other
Develop and apply modeling and mapping exposure assessment methods to
tools to link environmental and personal generate GIS displays for individualized
exposure data to identify at-risk populations exposure assessment in targeted studies
Biologic sensors Develop wearable personal sensors for Develop deployable in vivo (microscale
monitoring activity patterns and nanoscale) sensors for monitoring
Develop data management and analytic biologic responses to priority exposures
to support biologic sensing devices
Develop in vitro diagnostic sensors for Develop sensor networks
monitoring early biologic responses
to priority environmental factors
Toxicogenomicsa Select preferred technology platforms Conduct human and animal studies to
Develop data and technology standards validate molecular signatures as markers
Develop improved methods of sample of exposure, response and susceptibility,
preparation and analysis (throughput) and define biologic response pathways
Initiate human and animal studies to develop for priority exposures and responses
molecular signatures as markers of exposure,
response and susceptibility, and define
disease processes
Body burden assays Develop and apply assays to quantify priority Develop and apply new methods to assess
exposures in biologic samples biologically effective doses for priority
Improve methods of sample preparation exposures and mixtures
and analysis Conduct studies to link body burden with
Improve sample matrix selection, and assay biologically effective dose and environ-
sensitivity and selectivity mental levels for priority exposures
New methods, and improvements to existing methods, to personalize exposure assessment in human health research.
Specific activities needed to enhance technology development for exposure assessment are identified as first generation
(0–5 years from today) and second generation (5–10 years from today).
aRefers to global analysis of genes, gene expression transcripts (transcriptomics), proteins (proteomics), and metabolites
(metabolomics).
data sets have been generated by government
agencies for purposes of national surveillance
and environmental regulation. For example,
the U.S. EPA and the U.S. Geological Survey
(USGS) monitor ambient environmental 
contaminant levels, and the U.S. Census
Bureau collects information about population
demographics and land-use patterns. The data
sets can provide information about the
sources and concentrations of environmental
agents at specific monitor points, the nature
of the immediate neighborhood, and the
characteristics of the study population. The
environmental data sets tend to cover very
broad geographic scales, such as fixed moni-
toring stations and contaminant release points
for national air and water quality assessment
programs (U.S. EPA 2004). Although the
data are useful for defining trends in regional
environmental quality and assessing compli-
ance with environmental regulations, the scale
and resolution may not be appropriate for
estimating personal exposures in human
studies (Nuckols et al. 2004). Efforts to create
more comprehensive environmental data dis-
plays and mapping systems that may be used
in human health research are under way. For
example, the USGS, in collaboration with
the NIEHS, has launched the Environmental
Mercury Mapping, Modeling and Analysis
(EMMMA) website for visualizing the distri-
bution of mercury across geographic, tempo-
ral, and biologic scales (EMMMA 2004).
The system uses GIS technology to link dis-
tinct data sets on mercury levels in environ-
mental media (soil, stream sediments) and
multiple fish species and tissues. Web-based
mapping tools are used to analyze the mer-
cury data and generate local and national
maps of mercury distribution that can be
used in human research.
A number of epidemiologic studies have
used GIS technology to assess environmental
exposures. In many of the early studies, GIS
was used to define the study population and
to develop the exposure surrogate based on
the proximity of the study population to the
contaminant source. More recently, GIS has
been used in conjunction with computer-
based geographic models and analysis tools for
predicting contaminant transport and fate,
extrapolating between data points to identify
potential pathways and routes of exposure,
and defining the temporal and spatial distribu-
tion of exposure across the study population
(Beyea and Hatch 1999; Georgopoulos et al.
1997; Jarup 2004). For example, GIS-based
approaches have been used for developing
individual metrics for exposure to pesticides,
drinking water contaminants, and air pollu-
tants such as nitric oxide, sulfur dioxide, and
particulates (Bellander et al. 2001; Kunzli
et al. 2005; Nuckols et al. 2004). Only very
recently, researchers have been considering the
use of GIS to derive personal exposure esti-
mates by linking information about personal
activity and behavioral patterns with environ-
mental data (Hellstrom et al. 2004; Jarup
2004; Nuckols et al. 2004). Although no
applications of GIS in epidemiologic studies
have been reported, several researchers have
used GIS with global positioning systems
(GPS) to define activity patterns that could
conceivably be linked to environmental data
for exposure assessment (Elgethun et al. 2003;
Nuckols et al. 2004; Phillips et al. 2001). In
two studies, a GPS data recorder was used to
obtain time–location data that could be linked
with information about environmental expo-
sure to pesticides in children (Elgethun et al.
2003) and used to validate exposure informa-
tion collected by personal diaries (Phillips
et al. 2001). A recent report used GIS technol-
ogy to develop a household-level priority
model for childhood lead poisoning in North
Carolina (Miranda and Dolinoy 2005). The
model linked household location and age with
blood lead level and demographics to define
potentially at-risk individuals and subpopu-
lations. The model could be expanded to
include personal activity, health outcome, and
genetic information. Establishing temporal
and spatial linkages could be used to assess
potential exposure–disease relationships and
define genetically susceptible individuals
(Miranda and Dolinoy 2005). Information
about activity patterns could be collected from
study participants using biologic sensing
devices and GPS units. Using GIS to spatially
integrate personal behavior patterns with
environmental data will enable researchers to
develop hypotheses about exposure–disease
relationships that can be tested in focused
studies of potentially at-risk individuals or
subgroups of the population. Smaller, focused
studies provide an opportunity to use more
costly and exploratory technologies, such as
environmental or biologic sensors and toxico-
genomics, to develop more personalized meas-
ures of environmental exposure. In general,
environmental or biologic measurements with
tight coefficients of technical variation but
large ranges of real variation will be most
informative. If the environmental or biologic
variation is small or small in relation to
measurement error, the measurement will
have little utility for exposure estimation.
Biologic Exposure Methods
The greatest impediment to conducting
environmental epidemiologic studies is the
lack of accurate, quantitative measures of
exposure at points of human contact and
within the organism. Technologies based on
biologic sensors, toxicogenomics, and body
burden (biologic) measurements may be useful
in human studies to address these critical
information gaps.
Biologic sensors. A common limitation in
exposure assessment is the lack of information
about patterns of physical activity and behav-
ior that affect the likelihood of exposure, the
frequency and duration of exposure, and the
uptake and distribution of environmental
agents in the body. Personal dosimetry devices
are able to measure individual variables related
to activity such as motion, temperature, pres-
sure, energy use, respiratory function, and
heart rate (Balbatun et al. 2003; Cao et al.
2004; Jianrong et al. 2004; Kalinowski et al.
2004; Koo et al. 2004; Miljanic et al. 2003;
Mo and Smart 2004; Salimi et al. 2004).
Many of the devices have been applied suc-
cessfully in clinical, radiologic, and other
occupational and laboratory settings. For
application to epidemiology, the technologies
Personalized exposure assessment
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Figure 2. Conceptual strategy for integration of new exposure assessment technologies in human environ-
mental health research.
Identify priority diseases and plausible
environmental factors
Identify potential genetic determinants,
pathways, and model systems
Identify target study populations
Define genetic determinants of susceptibility
Conduct targeted exposure assessment
Establish functionality of gene variants for
susceptibility
Identify and validate markers
Describe gene–environment interactions in
exposure and disease
Design and implementation Technologies and approaches
Available scientific literature, public databases,
GIS coverages and expertise on exposure,
response and genetic factors for priority diseases;
computer-based biologic pathway mapping
systems; genetic and genome-wide databases
Ongoing (or new) human health studies with body
burden assays, tissue repositories, environmental
monitoring (macroscale to personal) for priority
exposures; GIS-based approaches
Genome screening, genetic association studies,
laboratory in vivo and in vitro studies (genetic
analysis, toxicogenomics)
Human and laboratory in vivo and in vitro studies of
biologic and environmental sensors, comparative
toxicogenomics, body burden assays, biologic
pathway mapping, functional analysis studies
require reengineering to combine them into a
single small device or set of portable devices
that provide readouts that can be integrated
over space and time. Wireless tracking devices,
global positioning systems, and videography
can be incorporated into the sensors, allowing
researchers to follow enrolled study partici-
pants as they move around. Biologic sensors,
some of which may contain tracking devices,
are being considered for use by the military in
homeland defense (Center for Nanoscale
Science and Technology 2004) but have not
been integrated into epidemiology study
designs. Inclusion of tracking devices in per-
sonal-dosimetry tools will enable researchers to
link data about external and internal exposures
with personal activity patterns. Establishing
such linkages provides a basis for developing
models for predicting personal biologic expo-
sure based on external measurements that are
more readily available in epidemiologic studies.
Biosensors are devices that contain a bio-
logic sensing agent, such as an enzyme, anti-
body, or microorganism, to detect the presence
of a specific analyte in the body. Detection of
the analyte produces a biologic change that is
converted by a transducer component into a
measurable output, such as an electrical or
optical signal (Mo and Smart 2004). Biologic
sensors hold great promise for improving
exposure assessment because many such
devices provide rapid, accurate, and quantita-
tive detection and monitoring of a variety of
exposures, including mixtures, at a personal
level (Bayley and Cremer 2001; Cao et al.
2002; Cui et al. 2001; Culha et al. 2004; Fehr
et al. 2005; Haruyama 2003; Jianrong et al.
2004; Mehrvar and Abdi 2004; Salimi et al.
2004; Vo-Dinh 2002).
There has been a renaissance in biologic
sensor development over the last several
decades. Nanoscale technologies are being pro-
posed for use in medical and basic-research
applications (National Cancer Institute 2004;
www.biosensors-congress.elsevier.com 2004).
Miniature sensors with micro- and even nano-
scale dimensions are currently being developed,
with many technologies available for labora-
tory- and research-based measurements. New
electrochemical and optical sensors, based on
such techniques as surface plasmon resonance,
surface enhanced Raman spectroscopy, fluores-
cence, and microelectrodes, offer promise for
personalizing exposure assessment. Engineered
materials such as polymers, smart materials,
nano- and microstructured materials, and
affinity-based reagents such as aptamers,
phage-display libraries, and single-chain anti-
bodies have been employed for sensing and
offer opportunities for providing integrated
analyses for environmental epidemiologic
studies. Because sensors have the potential to
measure continuously, they provide many
opportunities for improving our ability to
reduce uncertainties in characterizing human
exposure. However, continuous monitoring
will yield massive data sets that will require
sophisticated database structures and query
capabilities, as well as new biostatistical tools
for analysis and integration. Consequently,
studies incorporating biologic sensing tech-
nologies will require appropriate computa-
tional tools and support (Porod et al. 2004).
With their potentially small dimensions, sen-
sors can be integrated into networks to provide
global sensing networks in which continuous
spatiotemporal monitoring is achieved.
Network development is a complex undertak-
ing, however, and will not be feasible in the
near future. Nonetheless, activities needed to
develop the networks can be readily piggy-
backed onto current efforts to address home-
land security and public health infrastructure
(Brown 2004).
Toxicogenomics for defining molecular sig-
natures. Toxicogenomics is a broad field that
seeks to define, on a global basis, the levels,
activities, regulation, and interaction of genes,
mRNA transcripts (transcriptomics), proteins
(proteomics), and metabolites (metabolomics)
in a biologic sample or system. The molecular
signature is derived from the complete data set
of mRNA, protein, or metabolite signals from
a biologic sample using data-reduction
approaches. A useful signature is composed of
an ensemble of markers that allows exposures or
states to be distinguished with high sensitivity
and high specificity (Pepe et al. 2001).
Toxicogenomics methods are evolving at
different rates, largely because of trends in sci-
entific discovery, available funding, and ease of
platform development and validation. Overall,
the experimental methods are approachable,
although improvements are still needed to
increase sample throughput, quantification,
and information yield per sample and to
decrease costs. Toxicogenomics-based meth-
ods are widely used in laboratory settings to
develop biomarkers of exposure, early biologic
response, and susceptibility. The approaches
have been used for classifying exposures to a
variety of chemicals and drugs, for example,
hydrazine, 2-bromoethanamine, lead acetate,
cadmium, and acetaminophen based on
mechanism of action and dose; they have
been used for classifying health outcomes for
cardiovascular disease and cancer based on
disease status and severity (Brindle et al.
2002; Chevalier 2004; Choi et al. 2004;
Chung et al. 2002; Coen et al. 2003; Griffin
et al. 2001; Hamadeh et al. 2002; Holleman
et al. 2004; Holmes et al. 2000, 2001;
Kimura et al. 2004; Petricoin et al. 2004a,
2004b; Posadas et al. 2004; Robertson et al.
2000; Tallman et al. 2004; Troyer et al.
2004). Toxicogenomics approaches have been
used for predicting the mechanism of action
of toxicants and drugs (Gavanagh et al. 2000;
German et al. 2003; Phelps et al. 2002;
Toraason et al. 2004) and for characterizing
the functional significance of genetic poly-
morphisms (Raamsdonk et al. 2001; Suarez-
Merino et al. 2005). The primary basis of
classification and discovery in these studies is
the molecular signature. The signature itself
provides little information about the under-
lying mechanisms of biologic response.
However, once the discriminating elements of
the molecular signature are identified, bio-
logic function can be inferred by mapping
components to known biologic pathways and
verifying functionality in follow-up studies.
Misclassification of exposure and outcome
is an important source of bias in epidemiologic
studies, and most study designs provide little
opportunity to focus on biologic mechanisms
underlying the exposure–disease relationship.
Toxicogenomics-based methods are being
increasingly used in epidemiology and clinical
studies, but inclusion is sporadic, primarily due
to the lack of readily obtainable, stable, and
abundant sample material. Despite the enor-
mous promise of toxicogenomics for advancing
our understanding of the relationship between
environmental exposure and disease, the chal-
lenge has been, and will continue to be, the
development of genetic and biologic markers
that are predictive of adverse health outcomes
in both experimental and human studies.
Toxicogenomics provides an opportunity
to move beyond traditional approaches to
exposure assessment based on one chemical
agent in one environmental medium (air,
water, soil) at a time, to a more realistic view of
exposure involving multiple exposures, at
potentially low environmental concentrations,
and multiple biologic response pathways. This
comprehensive view of exposure is needed to
define complex exposure–disease relationships
and the interactions between genetic and envi-
ronmental factors in human disease. Achieving
this goal will require new information and
sophisticated modeling capabilities to annotate
the components of biologic pathways and to
describe their interactions under normal
homeostatic conditions and after perturbation
by environmental agents. Model development
is time consuming, however, and requires a
critical mass of appropriate data from human
and experimental laboratory studies to be col-
lected and organized. In the short term, molec-
ular signature studies conducted using
laboratory animals and human cells lines will
be useful for guiding the interpretation of
exposure data from epidemiologic studies.
Background levels of expression and vari-
ability for mRNA transcripts, proteins, and
metabolites in human tissues are currently not
known but must be defined if toxicogenomics
methods are to be used to assess personal expo-
sures in epidemiologic studies. Expression
levels are expected to vary widely because of
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differences in diet, lifestyle, health status, and
genetic predisposition. In addition, expression
changes due to low-level environmental expo-
sures may not be distinguishable from baseline,
given this inherent variability. Developing
background measures of expression for mRNA
transcripts, proteins, and metabolites in
biosamples will take time and require a critical
mass of data. Equally important is the need for
technology platforms that produce reliable,
quantitative, and stable measurements over
time. Standards are needed to assess the quality
and reliability of data and to facilitate data shar-
ing and compilation across multiple studies
using a variety of technology platforms. Efforts
to develop data and technology standards for
transcriptomics, proteomics, and metabolomics
are under way (Ball et al. 2004; Freeman 2004;
Henry 2004; Kaiser 2002; Lindon et al. 2003;
Omenn 2004; Orchard et al. 2004; Weis
2005). Preliminary findings suggest that data
reproducibility across laboratories is highest
when standardized data reporting requirements,
technology platforms, and experimental proto-
cols are used (Lindon et al. 2003; Weis 2005;
Yauk et al. 2004). These are important consid-
erations for designing epidemiologic studies to
ensure that meta-analyses and inferences can be
made across other populations.
Body burden (biologic) measurements.
Assays are available to measure individual body
burden or internal dose for a variety of environ-
mental agents, including heavy metals, phtha-
lates, and organic compounds [Barr et al. 2003;
Marin et al. 2004; Metcalf and Orloff 2004;
National Health and Nutrition Examination
Survey (NHANES) 2005; Pirkle et al. 1995].
Most of the assays are based on the quantifica-
tion of chemicals, their metabolites, or reaction
products in blood and urine samples. For most
chemicals, the assays produce reliable, quantita-
tive measurements. However, there are several
limitations of the available assays. Many assays
lack the sensitivity and specificity needed to
detect the broad range of compounds present in
biologic samples, and many assays have not
been validated at background levels in the envi-
ronment. Most assays can accommodate only
moderate sample throughput. Sample collec-
tion for blood is invasive and requires clinical
supervision and informed consent, which can
limit sample collection from infants and chil-
dren. Modern analytic methods have increased
sensitivity, thus requiring smaller sample vol-
umes, which are easier to obtain. Biologic mea-
surements of body burden are difficult to
interpret in relation to the biologically effective
dose and to early biologic response, but they
can provide helpful links to associated health
outcome. Population-based surveys such as
NHANES, a program of the Centers for
Disease Control and Prevention (CDC), pro-
vide information about the distribution of
many environmental chemicals in the U.S.
population (NHANES 2005). Such popula-
tion estimates are useful for benchmarking
measurements of individual exposure in epi-
demiologic studies but are not designed to
provide information about the relative contri-
bution of multiple dietary and lifestyle factors,
and the impact of genetic variability and stress
on susceptibility. These components of expo-
sure are critical to the understanding of dose in
the context of the likelihood of adverse effects
and the need for intervention.
A number of innovative, sensitive, and spe-
cific methods for measuring internal dose,
including biologically effective dose, are cur-
rently under development. New methods based
on traditional technologies such as chromatog-
raphy and mass spectrometry are being imple-
mented in the CDC biomonitoring program
(Barr et al. 2003). The methods are being used
in basic research to identify exposure biomark-
ers for environmental chemicals based on DNA
and protein adducts (Barr et al. 2003; Chen
et al. 1996; Perera et al. 2004; Swenberg 2004).
Quantification of DNA and protein biomarkers
also provides information about the role of
genetic polymorphisms in exposure susceptibil-
ity for important environmental compounds
such as PAHs (Perera et al. 2004; Swenberg
2004). The methods for biologic measurement
offer a wide range of sample collection matrices,
including hair, saliva, and tissue, and are capa-
ble of detecting a myriad of compounds in a
single sample. Continued development of these
methods is needed to solve problems in sample
collection and analysis, sample throughput, and
instrument sensitivity.
Additional research is needed to define the
functional significance of DNA and protein
adducts in human disease processes. Adduct
formation occurs naturally at a high frequency
in the human genome, making it difficult to
define the relative contribution of environ-
mental stressors to overall genomic alteration
and to assign a predictive value to specific
adduct formation for the risk of developing
human disease. Studies are needed to link bio-
logic measurements of body burden or adduct
formation to environmental concentrations of
exposure and to early biologic responses that
are predictive of adverse outcome. Establishing
such quantitative links will enable researchers
to develop more accurate models for predict-
ing internal dose based on external environ-
mental concentrations and for predicting
disease risk based on internal dose. With such
improvements, biologic measurements will
become an invaluable source of information
for personalizing exposure assessment in
human health studies.
A Strategy for the Future
Clearly, a continuum exists between biologic
markers of exposure and effect. Each step
along the way is an opportunity for prevention
through elimination or minimization of
exposure (Goldstein 1995) or, in the case of
beneficial exposures such as some dietary con-
stituents, augmentation. Realistically, single
markers may never provide a definitive answer
linking environmental exposure to disease
because disease processes involve complex
interactions among genes, environmental fac-
tors, and behavior. What is needed is a combi-
nation of genetic and biologic markers linking
critical events in the exposure–disease contin-
uum and a toolbox of methods to derive
them. The toolbox should include new experi-
mental technologies, and bioinformatics and
statistical tools (Molidor et al. 2003; Rebbeck
et al. 2004a), to assess the contribution of
multiple genetic variants in multiple biologic
pathways and health end points.
As an ad hoc Committee on Environ-
mental Exposure Technology Development,
we identified a toolbox of promising new
methods, and improvements to existing
methods, to personalize exposure assessment
in human health research (Table 1). Specific
activities needed to enhance technology devel-
opment for exposure assessment are identified
as first generation and second generation.
Highest priority is given to activities that
a) address needed improvements that are
readily identifiable and achievable and fill
critical gaps in knowledge and b) generate
information that is high quality, reliable, and
stable over time. The toolbox is intended to
facilitate technology applications in exposure
assessment in the public and private sectors. It
is clear that application of new technologies
will require multidisciplinary teams of expo-
sure analysts, epidemiologists, clinicians, mol-
ecular biologists, toxicologists, statisticians,
and bioinformaticians because the new
approaches cannot be applied successfully by
any one discipline independently.
We developed a conceptual framework for
integrating these new technologies in human
health research. The framework focuses on
common complex human diseases, such as
asthma and respiratory disease, neuro-
degenerative disease, and cancer, for each of
which there is substantial evidence of genetic
and environmental risk and each of which rep-
resents a significant public health burden.
Environmental agents can be used to under-
stand the disease processes by defining the
interaction between genes and environmental
factors in susceptible populations (Schwartz
et al. 2004). This framework combines human
and laboratory studies and incorporates new
technologies, as appropriate, to answer the bio-
logic questions of interest. For example, recent
work by Kiechl et al. (2002) used a prospective
population-based survey approach to identify
important genetic variants in the toll-like
receptor 4 (tlr4) that confer differential suscep-
tibility to airway inflammatory response from
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inhaled bacterial lipopolysaccharides (LPS). As
a follow-up, quantitative trait locus (QTL)
analysis and microarray-based gene expression
analysis were combined in a study of genetic
recombinant inbred mice strains with differen-
tial susceptibility to inhaled LPS to identify tar-
get genes (n = 28), in addition to tlr4, that may
have a causal or modifier role in the innate
response to LPS (Cook et al. 2004). Functional
genomics approaches can then be used to
assess the biologic significance of the target
genes and their protein products in biologic
pathways of response.
The framework identifies aspects of the
study design and implementation where new
approaches to exposure assessment can be
incorporated to identify genetic variants of
susceptibility, link genotype and phenotype
data for targeted diseases and exposures, and
assess the functional significance of targeted
gene variants and their interactions with
environmental factors. These aspects of the
study design and implementation are pre-
sented in Figure 2 and discussed briefly here.
Identification of priority diseases, plausible
environmental factors, genetic determinants,
pathways, and model systems. This identifica-
tion can be accomplished by reviewing the
available scientific literature and publicly avail-
able databases of environmental, health, and
genetic information. Many of the available data
sources are maintained by federal agencies such
as the National Institutes of Health (NIH), the
U.S. EPA, and the CDC. In addition, acade-
mic institutions, hospitals and health care facili-
ties, and industries have developed surveillance
programs for specific exposure and health
indices in targeted populations. A variety of
data sources, such as the GeneSNPs database
(Environmental Genome Project 2005) and the
International HapMap Project (2005), can be
used to identify target gene polymorphisms in
human and animal populations. Biologic path-
way mapping systems can provide insight into
potential biologic processes and research targets
for priority diseases. Workshops and meetings
can be convened for brainstorming and estab-
lishing research priorities. Participants would
include representatives from government agen-
cies, academia, and industry who are responsi-
ble for environmental and health surveillance,
and other scientific experts in exposure assess-
ment, molecular epidemiology, clinical medi-
cine, toxicogenomics, public health, toxicology,
and bioinformatics. Workshop participants
could define priority diseases and data sources
for plausible environmental exposures and
genetic susceptibility that are readily available or
feasible to obtain.
Identification of target study populations.
Given the exploratory nature of many new
exposure assessment technologies, it is not
practical to apply them in all human health
studies. One approach to study population
selection is to identify existing, well-designed
and controlled studies that could benefit from
the inclusion of new data to improve the expo-
sure assessment aspect of the study. The
NIEHS supports a number of environmental
health studies focusing on identifying genetic
and environmental risk factors and gene–envi-
ronment interactions in asthma and respiratory
disease, neurodegenerative disease, and cancers.
Other NIH institutes, the CDC, the U.S.
EPA, and other agencies have ongoing studies
that may be appropriate. The NHANES pro-
gram periodically seeks recommendations of
new assays for its studies. Highest priority
should be given to studies with clearly defined
disease outcomes, quantifiable environmental
exposures that may be plausibly related to the
disease, and an accessible study population.
Inclusion of new exposure assessment technolo-
gies into these ongoing studies, in particular to
derive personalized exposure measurements for
individuals or subpopulations at greatest risk of
exposure or disease, provides a cost-effective
approach to explore the practicality of their
implementation and the usefulness of the data
they generate. Specific study populations or
subpopulations for which body burden mea-
surements, personal monitoring data, and tis-
sue repositories are available or can be readily
obtained are particularly attractive candidates.
In addition, new study populations can be
identified using global screening tools such as
GIS-based technologies to identify specific sub-
populations with unusually high rates of the
disease or potentially elevated exposures for the
disease. The NIEHS and U.S. EPA support a
number of investigators who are currently
using GIS-based approaches as part of ongoing
research projects (Kunzli et al. 2005; Miranda
and Dolinoy 2005). Application of GIS-based
technologies, together with information about
personal activity patterns for the study partici-
pants, can be used to identify and target spe-
cific subpopulations for in-depth personalized
assessment of exposure.
Determinants of genetic variability and
susceptibility. Genotyping can be applied to
human studies to identify genetic variants that
may predispose individuals to environmental
exposure or disease. Genetic linkage and associ-
ation studies have been used to identify poten-
tial susceptibility genes for a number of
outcomes, including asthma and chronic
obstructive pulmonary disease (Meyers et al
2004; Sharma et al. 2004), inflammatory
response to inhaled bacterial pathogens and
atherogenesis (Kiechl et al. 2002), acute
myeloid leukemia (Rollinson et al. 2004), non-
Hodgkin lymphoma (Skibola et al. 2004), and
lung cancer (Liu et al. 2004). Some of these
studies involved genotyping families to define
disease-related genes that co-segregate with
DNA markers (Meyers et al. 2004; Sharma
et al. 2004). Well-established familial cohorts
are an excellent resource for conducting gene
discovery studies, especially for complex disor-
ders where disease subtypes (e.g., type I vs.
type II diabetes, breast cancer) can be discrimi-
nated within families (Merikangas 2003). Both
family and twin studies have been useful for
determining the relative contribution of
genetic and environmental factors in disease
occurrence, although the findings may not be
generalizable to other populations. Population-
based studies are useful for identifying the dis-
tribution of newly identified polymorphisms in
the population, in particular, susceptibility
genes that have low population frequencies.
Knowledge of population genetic structure
may provide insight into the functional rele-
vance of a genetic variant on a disease trait
(Rebbeck et al. 2004a). Public databases con-
taining information about single nucleotide
polymorphisms (SNPs) in human populations
can be used to identify target gene variants for
further study. Once genetic susceptibility genes
are identified, other approaches, such as nested
case–control studies for specific susceptibility
genotypes, may help define environmental fac-
tors that contribute to disease risk.
Targeted exposure assessment. Targeted
exposure assessment is needed to identify valid
genetic and biologic markers, determine the
functional significance of genetic variants, and
describe gene–environment interactions in dis-
ease. New technologies can be used to define
markers of external environmental exposure
based on human activity patterns and personal
monitoring, and markers of internal biologic
dose and response based on body burden mea-
surement, sensors, and toxicogenomics. For
many complex diseases, environmental risk
factors are not known; application of new
approaches provides an opportunity to identify
important environmental and behavioral risk
factors for disease. Exposure information gen-
erated using new approaches should be consid-
ered complementary to information collected
by study questionnaire or survey, in particular
regarding occupational, dietary, and lifestyle
factors. To the extent possible, quantitative
linkages between environmental data and per-
sonal exposure measurements should be estab-
lished as a basis for developing predictive
models for exposure assessment. Integrating
data from these new approaches into the study
design and data analysis phases will require
appropriate rigor of data and sample collection
and validation that is intrinsic to the best epi-
demiologic and clinical research. In addition,
improvements in analytic, statistical, and
bioinformatics tools will be needed to support
the integration of molecular, clinical, and epi-
demiologic data in human studies (Molidor
et al. 2003).
Concurrent studies in appropriate animal
models and primary human cell cultures should
be considered for developing and validating
Weis et al.
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genetic and biologic markers, establishing the
functional significance of candidate genetic
variants, and gaining mechanistic insight into
gene–environmental interactions in human
disease. Many model organisms are not as
genetically diverse as are humans but have
orthologous genes and biologic pathways that
are represented in humans. Comparative
studies in model systems with shared genes,
functions, and pathways provide the greatest
opportunity to define biologically relevant
responses to environmental exposures and the
impact of genetic variation on that response
in humans (Schwartz et al. 2004).
New technologies for personalizing expo-
sure assessment will benefit the scientific and
regulatory community by providing range-
finding and sensitivity matrices for specific
methods, developing baseline data on impor-
tant environmental factors, and improving
the results of exposure-model simulations.
Efforts to address genetic or genomic varia-
tion alone will have little value in personaliz-
ing human exposure assessment unless there
are effective linkages with information about
environmental and behavioral variables that
affect the likelihood of exposure and risk.
Therefore, future studies will require that
personal genetic information be linked with
estimated or measured personal exposure
data, while ensuring that individual privacy
is protected.
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information about the benefit of adopting a
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